<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00732069</url>
  </required_header>
  <id_info>
    <org_study_id>Fibrinolysis in Dialysis</org_study_id>
    <secondary_id>R01HL065193-08A2</secondary_id>
    <nct_id>NCT00732069</nct_id>
  </id_info>
  <brief_title>Study of Inflammation and Oxidative Stress in Persons Undergoing Dialysis</brief_title>
  <official_title>Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 2</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Little is known about how some drugs affect inflammation or clotting factors in people
      receiving hemodialysis. It is not yet known if these drugs help prevent heart damage as they
      do in people not undergoing hemodialysis or whether they could increase the risk of heart
      problems. The purpose of the study is to measure certain chemicals in the blood and see how
      those chemicals may change during hemodialysis when certain drugs are given.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  Cardiovascular disease in the leading cause of death in patients with chronic kidney
           disease undergoing hemodialysis.

        -  Traditional risk factors do not adequately predict cardiovascular morbidity and
           mortality in patients with chronic kidney disease.

        -  Increased oxidative stress, inflammation and impaired fibrinolysis contribute to
           cardiovascular risk in chronic kidney disease patients undergoing hemodialysis.

        -  Activation of the renin-angiotensin-aldosterone system(RAAS) may contribute to oxidative
           stress and inflammation in individuals with chronic kidney disease

        -  Activation of the kallikrein-kinin system during hemodialysis may increase fibrinolysis
           but may also contribute to inflammation in chronic kidney disease

        -  Despite data from clinical trials demonstrating that ARBs and ACE inhibitors decrease
           cardiovascular mortality, delay progression to cardiovascular disease and decrease the
           incidence of diabetes in the general population little is known about the impact of
           these agents on cardiovascular morbidity and mortality in patients with end- stage renal
           disease (ESRD) undergoing hemodialysis

        -  Angiotensin-converting enzyme(ACE) inhibitors and angiotensin receptor blockers (ARB)S
           differ in their mechanisms of action and their effects on inflammatory biomarkers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interleukin 1 Beta</measure>
    <time_frame>During dialysis after one week of study drug</time_frame>
    <description>Mean difference in interleukin 1 beta concentration during treatment with ramipril versus treatment with placebo</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>F2-Isoprostanes</measure>
    <time_frame>During dialysis after one week of study drug</time_frame>
    <description>Mean difference in F2-isoprostanes during dialysis between treatment with ramipril or valsartan and placebo</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>End Stage Renal Failure on Dialysis</condition>
  <condition>Complication of Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Placebo, then ramipril, then valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then valsartan, then ramipril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo, ramipril, valsartan: Subjects were treated sequentially with placebo, valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramipril, then placebo, then valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then placebo (once a day by mouth), then valsartan (160mg/day by mouth). Each drug was given for 7 days after a 3-week washout.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan, then placebo, then ramipril</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo, ramipril, valsartan: Subjects were treated sequentially with valsartan (160mg/day by mouth), then placebo (once a day by mouth), then ramipril (5mg/day by mouth). Each drug was given for 7 days after a 3-week washout.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramipril, then valsartan, then placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo, ramipril, valsartan: Subjects were treated sequentially with ramipril (5mg/day by mouth), then valsartan (160mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan, then ramipril, then placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>placebo, ramipril, valsartan: Subjects were treated sequentially with then valsartan (160mg/day by mouth), then ramipril (5mg/day by mouth), then placebo (once a day by mouth). Each drug was given for 7 days after a 3-week washout.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis</description>
    <arm_group_label>Placebo, then ramipril, then valsartan</arm_group_label>
    <arm_group_label>Placebo, then valsartan, then ramipril</arm_group_label>
    <arm_group_label>Ramipril, then placebo, then valsartan</arm_group_label>
    <arm_group_label>Valsartan, then placebo, then ramipril</arm_group_label>
    <arm_group_label>Ramipril, then valsartan, then placebo</arm_group_label>
    <arm_group_label>Valsartan, then ramipril, then placebo</arm_group_label>
    <other_name>matching placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis</description>
    <arm_group_label>Placebo, then ramipril, then valsartan</arm_group_label>
    <arm_group_label>Placebo, then valsartan, then ramipril</arm_group_label>
    <arm_group_label>Ramipril, then placebo, then valsartan</arm_group_label>
    <arm_group_label>Valsartan, then placebo, then ramipril</arm_group_label>
    <arm_group_label>Ramipril, then valsartan, then placebo</arm_group_label>
    <arm_group_label>Valsartan, then ramipril, then placebo</arm_group_label>
    <other_name>Ramipril 2.5mg/d for two days, then 5mg/d for 5 days.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis</description>
    <arm_group_label>Placebo, then ramipril, then valsartan</arm_group_label>
    <arm_group_label>Placebo, then valsartan, then ramipril</arm_group_label>
    <arm_group_label>Ramipril, then placebo, then valsartan</arm_group_label>
    <arm_group_label>Valsartan, then placebo, then ramipril</arm_group_label>
    <arm_group_label>Ramipril, then valsartan, then placebo</arm_group_label>
    <arm_group_label>Valsartan, then ramipril, then placebo</arm_group_label>
    <other_name>Valsartan 80mg/d for 2 days followed by 160mg/d for 5 days.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years or older

          -  On thrice-weekly chronic hemodialysis for at least 6 months

          -  Clinically stable, adequately dialyzed (single-pool Kt/V&gt; 1.2) thrice weekly, with
             polysulphone membrane for at least 3 consecutive months prior to study

        Exclusion Criteria:

          -  Body mass index &gt; 35 mg/kg

          -  History of functional transplant less than 6 months prior to study

          -  Use of anti-inflammatory medications other than aspirin &lt; 325 mg/d

          -  History of active connective tissue disease

          -  History of acute infectious disease within one month prior to study

          -  AIDS (HIV seropositivity is not an exclusion criteria)

          -  History of myocardial infarction or cerebrovascular event within 3 months

          -  Advanced liver disease

          -  Gastrointestinal dysfunction requiring parental nutrition

          -  Active malignancy excluding basal cell carcinoma of the skin

          -  History of ACE inhibitor-associated cough or angioedema

          -  Ejection fraction less than 40%

          -  Inability to discontinue ACE inhibitor or ARB

          -  Predialysis potassium repeatedly higher than 5.5 mmol/L (confirmed on a repeated blood
             draw)

          -  Anticipated live donor kidney transplant

          -  Use of vitamin E &gt;60 IU/d or vitamin C &gt;500 mg/d

          -  Pregnancy, breast-feeding or child-bearing potential

          -  History of poor adherence to hemodialysis or medical regimen

          -  Inability to provide consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy J Brown, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37323</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Gamboa JL, Pretorius M, Todd-Tzanetos DR, Luther JM, Yu C, Ikizler TA, Brown NJ. Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis. J Am Soc Nephrol. 2012 Feb;23(2):334-42. doi: 10.1681/ASN.2011030287. Epub 2011 Dec 8.</citation>
    <PMID>22158433</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2008</study_first_submitted>
  <study_first_submitted_qc>August 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2008</study_first_posted>
  <results_first_submitted>July 18, 2012</results_first_submitted>
  <results_first_submitted_qc>May 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 20, 2013</results_first_posted>
  <last_update_submitted>June 22, 2013</last_update_submitted>
  <last_update_submitted_qc>June 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Nancy J. Brown</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>inflammation</keyword>
  <keyword>kallikrein-kinin</keyword>
  <keyword>angiotensin receptor blockade</keyword>
  <keyword>angiotensin converting enzyme inhibition</keyword>
  <keyword>RAAS</keyword>
  <keyword>fibrinolysis</keyword>
  <keyword>endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Ramipril</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
    <mesh_term>Angiotensin-Converting Enzyme Inhibitors</mesh_term>
    <mesh_term>Enzyme Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment started in September 2008 and ended in January 2010 in Vanderbilt outpatients Dialysis Center.</recruitment_details>
      <pre_assignment_details>Three consented participants were excluded because of hyperkalemia, hypotension and uncontrollable hypertension.They were enrolled but did not start medication and were considered screen failures. The participants required a washout period from either an agiotensin receptor blocker or an angiotensin converting enzyme inhibitor.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo, Then Ramipril, Then Valsartan</title>
          <description>Participants were randomized to treatment with ramipril, valsartan and placebo in one of six possible sequences.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Valsartan, Then Ramipril</title>
          <description>Participants were randomized to treatment with ramipril, valsartan and placebo in one of six possible sequences.</description>
        </group>
        <group group_id="P3">
          <title>Ramipril, Then Placebo, Then Valsartan</title>
          <description>Participants were randomized to treatment with ramipril, valsartan and placebo in one of six possible sequences.</description>
        </group>
        <group group_id="P4">
          <title>Valsartan, Then Placebo, Then Ramipril</title>
          <description>Participants were randomized to treatment with ramipril, valsartan and placebo in one of six possible sequences.</description>
        </group>
        <group group_id="P5">
          <title>Ramipril, Valsartan, Then Placebo</title>
          <description>Participants were randomized to treatment with ramipril, valsartan and placebo in one of six possible sequences.</description>
        </group>
        <group group_id="P6">
          <title>Valsartan, Ramipril, Then Placebo</title>
          <description>Participants were randomized to treatment with ramipril, valsartan and placebo in one of six possible sequences.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Study Drug</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout After First Study Drug</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Study Drug</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout After Second Study Drug</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Third Study Drug</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>After a three week washout period, the subject will be undertake 3 study periods with one of three treatments, placebo, ramipril or valsartan</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.5" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Interleukin 1 Beta</title>
        <description>Mean difference in interleukin 1 beta concentration during treatment with ramipril versus treatment with placebo</description>
        <time_frame>During dialysis after one week of study drug</time_frame>
        <population>All participants who completed the three arm treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Ramipril</title>
            <description>After a three week washout period, the subject will be undertake 3 study periods with one of three treatments, placebo, ramipril or valsartan</description>
          </group>
          <group group_id="O2">
            <title>Valsartan</title>
            <description>After a three week washout period, the subject will be undertake 3 study periods with one of three treatments, placebo, ramipril or valsartan</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>After a three week washout period, the subject will be undertake 3 study periods with one of three treatments, placebo, ramipril or valsartan</description>
          </group>
        </group_list>
        <measure>
          <title>Interleukin 1 Beta</title>
          <description>Mean difference in interleukin 1 beta concentration during treatment with ramipril versus treatment with placebo</description>
          <population>All participants who completed the three arm treatment.</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.18" spread="3.56"/>
                    <measurement group_id="O2" value="2.16" spread="2.16"/>
                    <measurement group_id="O3" value="1.44" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>F2-Isoprostanes</title>
        <description>Mean difference in F2-isoprostanes during dialysis between treatment with ramipril or valsartan and placebo</description>
        <time_frame>During dialysis after one week of study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ramipril</title>
            <description>After a three week washout period, the subject will be undertake 3 study periods with one of three treatments, placebo, ramipril or valsartan</description>
          </group>
          <group group_id="O2">
            <title>Valsartan</title>
            <description>After a three week washout period, the subject will be undertake 3 study periods with one of three treatments, placebo, ramipril or valsartan</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>After a three week washout period, the subject will be undertake 3 study periods with one of three treatments, placebo, ramipril or valsartan</description>
          </group>
        </group_list>
        <measure>
          <title>F2-Isoprostanes</title>
          <description>Mean difference in F2-isoprostanes during dialysis between treatment with ramipril or valsartan and placebo</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.55" spread="27.53"/>
                    <measurement group_id="O2" value="59.03" spread="29.39"/>
                    <measurement group_id="O3" value="50.23" spread="22.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ramipril</title>
          <description>All subjects receiving ramipril</description>
        </group>
        <group group_id="E2">
          <title>Valsartan</title>
          <description>All subjects receiving valsartan</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>All subjects receiving placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular ischemia</sub_title>
                <description>Patient develop acute occipital infarct without evidence of hemorrhage within the 3 weeks washout period after receiving placebo treatment. The stroke was not felt to be study related by the Data and Safety Monitoring Committee for this study</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>One event each during ramipril, valsartan, placebo treatment</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <description>Occurred during placebo</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Both episodes of nausea occurred during valsartan treatment.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <description>1 event during valsartan, one in a subject during placebo</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain not cardiac</sub_title>
                <description>Event occurred during placebo</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dry cough</sub_title>
                <description>Occurred during placebo</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising after falling</sub_title>
                <description>Occurred in subject taking placebo</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular acces complication</sub_title>
                <description>occurred during placebo</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Nancy J. Brown</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>615-343-8701</phone>
      <email>nancy.j.brown@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

